Related Experiment Video
Updated: Jun 10, 2026
07:44
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
Serum and urinary metabonomic study of human osteosarcoma
Zhiyu Zhang1, Yunping Qiu, Yingqi Hua
1Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, PR China.
Journal of Proteome Research
|August 10, 2010
Summary
Metabolic profiling reveals distinct signatures in osteosarcoma (OS) patients, showing disrupted energy metabolism, including glycolysis and the TCA cycle. These findings highlight key metabolic alterations in pediatric bone cancer.
Area of Science:
- Biochemistry
- Oncology
- Metabolomics
Background:
- Osteosarcoma (OS) is the most common pediatric bone cancer.
- Current research primarily focuses on genetic and protein alterations.
- Metabolic variations in OS remain poorly understood.
Purpose of the Study:
- To investigate metabolic alterations in osteosarcoma patients.
- To identify a characteristic metabolic signature of OS using metabolomics.
- To differentiate OS patients from benign bone tumor patients and healthy controls.
Main Methods:
- Gas chromatography-mass spectrometry (GC-MS) for small-molecule metabolite profiling.
- Analysis of serum and urine samples from 24 OS patients, 19 benign bone tumor patients, and 32 healthy controls.
- Orthogonal partial least-squares-discriminant analysis (OPLS-DA) for data interpretation.
Main Results:
- Clear separation between healthy controls and bone tumor patients was observed.
- OS patients exhibited disrupted energy metabolism, including down-regulated TCA cycle and glycolysis.
- Other alterations included down-regulated lipid metabolism, dysregulated sugar levels, and up-regulated amino acid, glutathione, and polyamine metabolism.
Conclusions:
- Metabolomic analysis provides a distinct metabolic signature for osteosarcoma.
- Disrupted metabolic pathways are characteristic of OS carcinogenesis.
- These findings may offer novel biomarkers for OS detection and diagnosis.
